Friday, 6 November 2026
M
Meridian Globe
Live briefing
Malaysia's main opposition calls for greater power for states— 日经 Nikkei AsiaJapan logistics startups expand cold food networks in Malaysia, Vietnam— 日经 Nikkei AsiaFast-growing India is the next North America for Japan's Marubeni: CEO— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaUS midterms live: Nasdaq plunges 5.5% on AI regulation fears— 日经 Nikkei AsiaMalaysia's main opposition calls for greater power for states— 日经 Nikkei AsiaJapan logistics startups expand cold food networks in Malaysia, Vietnam— 日经 Nikkei AsiaFast-growing India is the next North America for Japan's Marubeni: CEO— 日经 Nikkei AsiaToyota to bring Celica back to premier rally racing after 32-year break— 日经 Nikkei AsiaU.S. Steel grows to 40% of Nippon Steel profit as prices surge— 日经 Nikkei AsiaThe price of building Japanese stealth frigates in Australia— 日经 Nikkei AsiaMcDonald's wages war on KFC in Japan as consumers crave chicken— 日经 Nikkei AsiaUS midterms live: Nasdaq plunges 5.5% on AI regulation fears— 日经 Nikkei Asia

[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial

Source 柳叶刀 Lancet15d ago
Summary

In patients with locally advanced dMMR colon cancer, treatment with ipilimumab and nivolumab before surgery resulted in a 3-year disease-free survival and 5-ye…

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
United Kingdom
Language
English
Item ID
health-26a46075

Comments 0 comments

No comments yet. Be the first.

[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial · Meridian Globe